Saatci, Ozge https://orcid.org/0000-0002-0124-044X
Alam, Rashedul
Huynh-Dam, Kim-Tuyen
Isik, Aynur
Uner, Meral https://orcid.org/0000-0001-9927-1246
Belder, Nevin https://orcid.org/0000-0001-9353-9387
Ersan, Pelin Gulizar https://orcid.org/0000-0003-3637-4090
Tokat, Unal Metin https://orcid.org/0000-0003-0026-368X
Ulukan, Burge https://orcid.org/0000-0002-1101-8834
Cetin, Metin
Calisir, Kubra https://orcid.org/0000-0002-6204-1022
Gedik, Mustafa Emre
Bal, Hilal https://orcid.org/0000-0003-1668-6070
Sener Sahin, Ozlem
Riazalhosseini, Yasser
Thieffry, Denis
Gautheret, Daniel
Ogretmen, Besim https://orcid.org/0000-0002-1019-5660
Aksoy, Sercan https://orcid.org/0000-0003-4984-1049
Uner, Aysegul
Akyol, Aytekin
Sahin, Ozgur https://orcid.org/0000-0002-8033-7089
Funding for this research was provided by:
American Cancer Society (RSG-19-194-01-CSM)
Foundation for the National Institutes of Health (R01CA251374)
Foundation for the National Institutes of Health (R01CA267101)
Foundation for the National Institutes of Health (C06 RR015455)
Foundation for the National Institutes of Health (P30 GM103339)
Susan G. Komen (GTDR17500160)
TUBITAK-CNRS Bilateral Grant
Article History
Received: 21 November 2023
Revised: 5 June 2024
Accepted: 6 June 2024
First Online: 15 June 2024
Competing interests
: O.S. is the co-founder of OncoCube Therapeutics LLC, the founder and president of LoxiGen, Inc., and the scientific advisory board member of A2A Pharmaceuticals. The other authors declare no potential competing interests.
: The study was approved by the NonāInterventional Clinical Research Ethics Committee of Hacettepe University (approval no: 2020/02-40). Informed consent was obtained from all patients.